Petros Pharmaceuticals initiates self-selection study for STENDRA

Petros Pharmaceuticals announces initiation of a self-selection study using the Drug Facts Label tested during its previously announced label comprehension study. Petros now launches this self-selection study in a simulated OTC setting that allows potential users to determine if they are appropriate candidates to use STENDRA based on their understanding of the label and personal medical history. This study is akin to a Phase 2 study in clinical development sequencing and is the next step in the Company’s FDA-guided pathway towards a possible OTC version of STENDRA, the Company’s prescription erectile dysfunction drug. At a recent meeting with the Company, the FDA provided encouraging guidance about the STENDRA DFL, paving the way for Petros to enter the next phase of research in the OTC development program, a Self-Selection Study. The FDA was forthcoming about its appreciation of the potential public health benefit of addressing men’s sexual health with nonprescription medication to treat ED.